MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external Data Monitoring Committee (eDMC) review.
The study (NCT06136559) investigated the non-covalent bruton’s tyrosine kinase (BTK) inhibitor in patients with chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia (SLL), and other malignancies to assess expected clinical outcomes.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The eDMC reviewed trial data and advised that the clinical advantages offered by the candidate might fail to surpass the observed patient risks.
Following an exhaustive evaluation of the complete dataset, the company confirmed the safety assessment, deciding to permanently halt the Phase III BELLWAVE-011 clinical investigation.
The decision consequently led MSD to terminate its wider BELLWAVE clinical development programme, which includes two additional Phase III trials, BELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851).
The company is informing trial investigators and advising enrolled patients to speak with their doctors about next steps and alternative therapies.
Data analyses across the studies are still underway, and MSD, also known as Merck and Co, plans to share the complete findings with the scientific community.
MSD research laboratories senior vice-president and global oncology clinical development head Dr Marjorie Green said: “Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical programme.
“We are grateful to all of the patients, caregivers and investigators for their many contributions that made these studies possible.
“We continue to pursue solutions for patients with haematologic malignancies and focus on advancing our haematology pipeline to help more patients with blood cancers.”
Nemtabrutinib is described as an investigational, oral therapy designed to impede oncogenic B-cell receptor signalling mechanisms.
CLL and SLL are among the most common haematological malignancies in adults. According to GlobalData’s Chronic Lymphocytic Leukemia: Opportunity Assessment and Forecast – Update report, diagnosed prevalent cases of CLL/SLL in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) are expected to increase from 429,348 cases in 2026 to 478,279 cases by 2032. GlobalData is the parent company of Clinical Trials Arena.
Targeted therapies, including BTK inhibitors and BCL2 inhibitors used alone or in combination, have become standard-of-care options for treatment-naïve CLL/SLL. However, an important unmet need remains for fixed-duration regimens that can deliver deep remissions, durable treatment-free intervals, and manageable toxicity, particularly in high-risk patients.
